# NADPH Oxidase Correction in mRNA-transfected Granulocyte-enriched Cells in Chronic Granulomatous Disease (CGD)

> **NCT05189925** · PHASE1 · RECRUITING · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 25 (estimated)

## Conditions studied

- Chronic Granulomatous Disease
- Infection

## Interventions

- **BIOLOGICAL:** gp91 Grans

## Key facts

- **NCT ID:** NCT05189925
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-07-22
- **Primary completion:** 2026-07-01
- **Final completion:** 2026-07-01
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05189925

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05189925, "NADPH Oxidase Correction in mRNA-transfected Granulocyte-enriched Cells in Chronic Granulomatous Disease (CGD)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05189925. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*